Cargando…
Type 2 myocardial infarction and myocardial injury: eligibility for novel medical therapy to derisk clinical trials
BACKGROUND: Patients with type 2 myocardial infarction (T2MI) and other mechanisms of nonthrombotic myocardial injury have an unmet therapeutic need. Eligibility for novel medical therapy is generally uncertain. METHODS: We predefined colchicine, eplerenone and ticagrelor as candidates for repurposi...
Autores principales: | Sykes, Robert, Briscoe, Michael, Krysztofiak, Thomas, Peck, Oliver, Mangion, Kenneth, Berry, Colin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174491/ https://www.ncbi.nlm.nih.gov/pubmed/34083388 http://dx.doi.org/10.1136/openhrt-2021-001633 |
Ejemplares similares
-
Sex-based associations with microvascular injury and outcomes after ST-segment elevation myocardial infarction
por: Maznyczka, Annette Marie, et al.
Publicado: (2019) -
Interphysician agreement on subclassification of myocardial infarction
por: Gard, Anton, et al.
Publicado: (2018) -
Creatine kinase is associated with bleeding after myocardial infarction
por: Brewster, Lizzy Maritza, et al.
Publicado: (2020) -
Sex differences in investigations and outcomes among patients with type 2 myocardial infarction
por: Kimenai, Dorien M, et al.
Publicado: (2021) -
Effect of cardiosphere-derived cells on segmental myocardial function after myocardial infarction: ALLSTAR randomised clinical trial
por: Ostovaneh, Mohammad R, et al.
Publicado: (2021)